Shunji Takahashi - Concepedia

Author

Shunji Takahashi

Japanese Foundation For Cancer Research ORCID

Also Known As

Hirofumi Mukai, Makoto Tahara, Mitani Hiroki, S Takahashi, S. TAKAHASHI, S. Takahashi, SHUNJI TAKAHASHI, Shunji TAKAHASHI, Shunji Takahashi, Susumu Okano

612

Publications

15.2K

Citations

H-Index

129

Concepts

All Affiliations

Japanese Foundation For Cancer Research The Cancer Institute Hospital National Cancer Center Hospital East Aichi Cancer Center Hokkaido University Hospital

About

Shunji Takahashi is an author at Japanese Foundation For Cancer Research specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	34	82	7.1K
2	Health Sciences	10	10	544
3	Public Health	3	3	96
4	Nursing	1	1	79
5	Anesthesia	1	1	30

Shunji Takahashi

189

Publications

12.3K

Citations

H-Index

Page 1

	Year	Citations
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study Barbara Burtness, Kevin J. Harrington, Richard Greil, The Lancet Neoadjuvant TherapyChemotherapy Versus CetuximabMedicinePathologyHead And Neck Cancer	2019	3K
Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low–Expressing Advanced Breast Cancer: Results From a Phase Ib Study Shanu Modi, Haeseong Park, Rashmi K. Murthy, Journal of Clinical Oncology	2020	786
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study Kenji Tamura, Junji Tsurutani, Shunji Takahashi, The Lancet Oncology Breast OncologyOncologyBreast CancerPharmacotherapyCancer Treatment	2019	343
Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors Junji Tsurutani, Hiroji Iwata, Ian E. Krop, Cancer Discovery	2020	337
Bisphosphonate-related osteonecrosis of the jaw: position paper from the Allied Task Force Committee of Japanese Society for Bone and Mineral Research, Japan Osteoporosis Society, Japanese Society of Periodontology, Japanese Society for Oral and Maxillofacial Radiology, and Japanese Society of Oral and Maxillofacial Surgeons Toshiyuki Yoneda, Hiroshi Hagino, Toshitsugu Sugimoto, Journal of Bone and Mineral Metabolism Japanese SocietyBone DiseaseBone HealthMedicineDistraction Osteogenesis	2010	269
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study Kohei Shitara, Hiroji Iwata, Shunji Takahashi, The Lancet Oncology OncologyGastrointestinal OncologyGastroenterologyPathologyCancer Treatment	2019	226
Trabectedin monotherapy after standard chemotherapy versus best supportive care in patients with advanced, translocation-related sarcoma: a randomised, open-label, phase 2 study Akira Kawai, Nobuhito Araki, Hideshi Sugiura, The Lancet Oncology Surgical OncologyTrabectedin MonotherapyMedicineSurgeryCancer Treatment	2015	215
Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Neuroendocrine Tumors: Results From the Phase II KEYNOTE-158 Study Jonathan Strosberg, Nobumasa Mizuno, Toshihiko Doi, Clinical Cancer Research	2020	214
Pooled analysis of drug-related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies Charles A. Powell, Shanu Modi, Hiroji Iwata, ESMO Open	2022	202
Lenvatinib for Anaplastic Thyroid Cancer Makoto Tahara, Naomi Kiyota, Tomoko Yamazaki, Frontiers in Oncology	2017	188

Page 1